Company news

Theravance Biopharma, Inc. news in 2025

Theravance Biopharma, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

November 19, 2025

Theravance Biopharma to Participate in Upcoming Investor Conferences

November 18, 2025

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 9, 2025

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

October 28, 2025

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

October 26, 2025

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

October 15, 2025

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

October 13, 2025

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 1, 2025

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

August 24, 2025

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 11, 2025

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

July 27, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference

July 22, 2025

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

June 25, 2025

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

June 1, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

May 8, 2025

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

April 27, 2025

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

April 23, 2025

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

April 6, 2025

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

March 26, 2025

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

February 11, 2025

Calls in 2025

Decks in 2025